

29 **Abstract**

30 Leukocyte telomere length (LTL) is associated with multiple conditions, including
31 cardiovascular diseases and neoplasms, yet their differential associations across diverse
32 individuals are largely unknown. We estimated LTL from blood-derived whole genome
33 sequences in the *All of Us* Research Program (n=242,494) with diverse backgrounds across the
34 United States. LTL was associated with lifestyle, socioeconomic status, biomarkers,
35 cardiometabolic diseases, and neoplasms with heterogeneity across genetic ancestries and sexes.
36 Geographical analysis revealed that significantly longer LTL clustered in the West Coast and
37 Central Midwest, while significantly shorter LTL clustered in the Southeast in the United States,
38 accounting for age, sex, and genetic ancestry. Genome-wide association study and meta-analysis
39 with the UK Biobank (n=679,972) found 234 non-overlapping loci, of which 36 were novel. We
40 identified 4 novel loci unique to non-European-like populations and one specific to females.
41 Rare variant analysis uncovered 7 novel genes, providing new functional insights. Our study
42 highlighted previously underappreciated contextual heterogeneities of phenomic and genomic
43 associations with LTL.

44 Leukocyte telomere length (LTL) has been widely regarded as a marker of biological aging^{1,2}.
45 Telomeres, composed of repetitive TTAGGG sequences and associated proteins, span 3 to 15 kb
46 at the ends of chromosomes and shorten during cellular division in cells with imperfect
47 telomerase activity. This gradual shortening leads to reduced telomere length as individuals age.
48 Indeed, studies have demonstrated that shorter LTL is associated with a variety of age-related
49 diseases, such as cardiovascular diseases^{3,4}, while longer LTL is associated with healthier
50 lifestyle⁵⁻⁹ and less stressful living conditions¹⁰⁻¹³.

51 Beyond a marker, genetic studies indicate that shorter telomere length might cause increased risk
52 for coronary artery disease (CAD) and interstitial lung disease, and decreased risk for some
53 cancers^{9,14}. Cell proliferative conditions, including neoplasms, have varied associations with
54 telomere length. Mendelian short telomere syndromes are enriched for malignant neoplasms¹⁵,
55 while Mendelian longer telomere is associated with increased risks of various types of
56 neoplasms^{16,17}. Given that both longer and shorter telomeres are markers or potential causes of
57 diseases, granular studies in telomere length are warranted to effectively utilize telomere
58 information for propelling population health.

59 Although telomere length and its attrition rate can vary across different tissues, LTL has served
60 as a representative marker due to relative ease of accessibility and significant correlation of
61 telomere lengths across tissues¹⁸. Notably, more subtle inter-individual variation in LTL has
62 been linked to increased risks of solid tumors arising from multiple organs⁴. LTL has facilitated
63 large-scale cohort studies of telomere length, yielding important general insights into the
64 relationship between telomere length and diseases/conditions^{4,9,19-21}.

65 There has been known heterogeneity in LTL itself and in associations between LTL and health-
66 related traits, including longer LTL but faster attrition rate in African than European^{8,22,23}.
67 However, the lack of a large-scale cohort encompassing multiple genetic ancestries with
68 genomic assay on the same platform has hindered detailed investigations of such heterogeneities.
69 Furthermore, the conventional measurement of telomere length by quantitative polymerase chain
70 reaction (qPCR) using a short range of genome as the control is affected by variations at the
71 control genome, which can be significantly different across genetic ancestries. This is evidenced
72 by the previous genome-wide association study (GWAS) in the UK Biobank (UKB) with qPCR,
73 which found that an African-like population (AFR)-specific variant significantly affected the
74 result⁴.

75 More recent methods to estimate telomere length from whole genome sequence (WGS) data
76 leverage the entire genome as the control and, thus, are expected to be more robust to differences
77 in particular variants. So far, such aforementioned bias has not yet been reported using these
78 methods^{24,25}.

79 Here, we estimated LTL from 242,494 blood-derived WGS data in the *All of Us* Research
80 Program (AoU) accompanied by rich phenotypes in the diverse U.S. population. We described
81 the demographic and geolocal heterogeneity of LTL and its heterogeneous associations with
82 health-related traits across genetic ancestries and sexes. We further performed GWAS for

83 common variants and rare variant association analysis (RVAS), followed by meta-analysis with
84 UKB. We further described genetic ancestry- and sex-specific genomic predispositions to LTL
85 (Fig. 1).

86

87 **Results**

88 **Estimating leukocyte telomere length (LTL) in the *All of Us* Research Program (AoU)**

89 We estimated LTL from 242,494 high-quality blood-derived WGS in AoU with covariate
90 information, including age, genetically inferred sex (Supplementary Fig. 1), of whom mean age
91 (standard deviation) was 51.65 (16.9), 147,779 (60.9%) were female, and 131,633 (54.3%) were
92 genetically inferred as European-like (EUR). Briefly, we estimated LTL using modified
93 TelSeq²⁶, then adjusted for sequencing heterogeneity by regressing it out against principal
94 components (PCs) derived from sequencing depth using mosdepth²⁷ and NGS-PCA²⁴ (Method,
95 Extended Data Fig. 1).

96 The PC-regressed-out LTL was strongly correlated with age, sex, and genetic ancestry (Fig. 2a),
97 aligning with previous reports^{9,22,23}. Age was more influential in genetically inferred African-like
98 population (AFR, $\beta = -0.0340$, $P = 2.1 \times 10^{-846}$) than EUR ($\beta = -0.0327$, $P = 3.5 \times 10^{-1184}$,
99 $P_{\text{Ancestry_heterogeneity}} = 9.5 \times 10^{-8}$), aligning with previous reports that African individuals have
100 higher age-related LTL attrition rates than European individuals^{22,23} (Fig. 2b). Heterogeneity
101 across genetic ancestries for the effect of age on LTL was more significant in males
102 ($P_{\text{Ancestry_heterogeneity}} = 1.3 \times 10^{-12}$) than in females ($P_{\text{Ancestry_heterogeneity}} = 0.017$).

103 **LTL was associated with health-related traits heterogeneously across genetic ancestries 104 and sexes in AoU**

105 We examined whether LTL was observationally associated with health-related traits in AoU,
106 adjusting for age, sex, genetic PCs, and sequencing site. We focused on 5 categories previously
107 reported to be associated with LTL in various cohorts: anthropometrics^{4,28}, vital signs^{4,29,30},
108 biomarkers^{4,31}, lifestyle^{8,9}, and socioeconomic status^{9,20}. AoU replicated many of these
109 associations, except the systolic blood pressure (SBP), which was not significant ($\beta = -0.00383$,
110 $P = 0.094$), while higher SBP was reported to be associated with shorter LTL in UKB and other
111 cohorts^{4,30} (Fig. 2c, Supplementary Table 1). Of note, alcohol participation ever in life was
112 associated with longer LTL in AoU ($\beta = 0.0532$, $P = 4.0 \times 10^{-11}$); however, the amount of alcohol
113 was associated with shorter LTL (3 or more drinks per day on average: $\beta = -0.116$, $P = 3.5 \times 10^{-58}$)
114 as reported previously^{8,32}.

115 Next, we tested heterogeneity of these associations across genetic ancestries and sexes. Fifteen
116 out of 24 tested traits showed significant heterogeneity by genetic ancestry after Bonferroni
117 correction ($P < 0.0021$), and 9 phenotypes showed significant heterogeneity by sex ($P < 0.0021$,
118 Fig. 2d). All seven tested socioeconomic status showed heterogeneous associations with LTL by
119 genetic ancestry. Two socioeconomic statuses, “without living partner” ($\beta_{\text{Female}} = -0.104$, $\beta_{\text{Male}} =$

120 -0.154 ; $P_{\text{Sex_heterogeneity}} = 2.2 \times 10^{-4}$) and “*stable house concern*” ($\beta_{\text{Female}} = -0.134$, $\beta_{\text{Male}} = -0.189$;
121 $P_{\text{Sex_heterogeneity}} = 1.3 \times 10^{-4}$) showed heterogeneous associations with LTL by sex. While SBP was
122 not associated with LTL overall, higher SBP was significantly associated with shorter LTL in
123 females ($\beta = -0.0116$, $P = 5.1 \times 10^{-5}$) but not in males ($\beta = 0.00947$, $P = 0.014$, $P_{\text{Sex_heterogeneity}} =$
124 8.4×10^{-4}). Sex heterogeneities in the LTL-SBP association were most pronounced in EUR
125 ($P_{\text{Sex_heterogeneity}} = 8.7 \times 10^{-4}$) among genetic ancestries.

126 We computed polygenic scores for LTL (LTL-PGS) in EUR of AoU participants using GWAS
127 summary statistics from UKB (Method). LTL-PGS were significantly associated with
128 anthropometrics, heart rate, smoking, alcohol-related behavior, and socioeconomic status,
129 showing concordant directions with measured LTL (Extended Data Fig. 2, Supplementary Table
130 1). Residualized LTL by LTL-PGS (LTL-residual) yielded similar results to those of measured
131 LTL with attenuated effect estimates, which was in line with a previous report²¹.

132 **LTL was associated with diseases and conditions heterogeneously across genetic ancestries** 133 **and sexes in AoU**

134 We conducted a phenome-wide association study to identify the associations between LTL and a
135 broad spectrum of diseases and conditions. We tested the associations between LTL and
136 phecodes^{33,34} using the logistic regression model adjusting for age, sex, first 10 genetic PCs, and
137 sequencing site in AoU. After Bonferroni correction, increased risk of 54 phecodes out of 1,754
138 tested was significantly ($P < 2.9 \times 10^{-5}$) associated with longer LTL, while increased risk of 572
139 phecodes was associated with shorter LTL (Fig. 3a, Supplementary Table 2).

140 Given the unique relationships between LTL and neoplasms, we inspected the details of cell
141 proliferative conditions, including neoplasms, dysplasia, and cysts (Supplementary Table 2), by
142 assessing the number of significant associations with shorter and longer LTL. Neoplasms have
143 been associated with longer LTL due to the allowance of more cell division (telomere length is
144 the cause of the disease), but tumor cells have short telomeres due to accelerated cell cycles^{35,36}
145 (telomere length is the consequence of the disease). Thus, we distinguished between non-
146 hematologic and hematologic, considering that we measured telomere length in hematologic
147 cells. Among the 49 phecodes for non-hematologic cell proliferative conditions significantly
148 associated with LTL, 85.7% (42/49) of phecodes were associated with longer LTL. In
149 comparison, all the phecodes (11/11) for hematologic cell proliferative conditions with
150 significant LTL-association were associated with shorter LTL. On the other hand, among 566
151 phecodes for non-cell proliferative conditions significantly associated with LTL, 97.8%
152 (554/566) were associated with shorter LTL.

153 Next, we tested if the associations were heterogeneous across genetic ancestries and sexes by
154 Cochran’s Q test. Fifty-two phecodes were associated with LTL significantly heterogeneously
155 across genetic ancestries ($P_{\text{Ancestry_heterogeneity}} < 2.9 \times 10^{-5}$), including heart failure, hypertension,
156 gastroesophageal reflux disease, diabetes, renal failure, tobacco use disorders, and respiratory

157 failure. Seven phecodes were associated with LTL significantly heterogeneously between sexes
158 ($P_{\text{Sex_heterogeneity}} < 2.9 \times 10^{-5}$), including peripheral vascular disease and obstructive sleep apnea
159 (Fig. 3b, Supplementary Fig. 2). Obesity was heterogeneous both across genetic ancestries and
160 sexes, in line with the findings in weight and body mass index (BMI, Fig. 2d).

161 We tested the association of LTL-PGS with phecodes in EUR. We found that 28 phecodes were
162 significantly associated with LTL-PGS ($P < 2.9 \times 10^{-5}$, Extended Data Fig. 3a, Supplementary
163 Table 2). Twenty-two phecodes significantly associated with longer LTL-PGS were all cell
164 proliferative conditions, including both non-hematologic and hematologic neoplasms. On the
165 contrary, 6 phecodes associated with shorter LTL-PGS were all non-cell proliferative conditions.
166 LTL-residual showed similar association patterns with LTL (Extended Data Fig. 3b,
167 Supplementary Table 2).

168 We specifically curated (Method) and tested the associations for the following conditions: non-
169 hematologic neoplasms and hematologic neoplasms; clonal hematopoiesis of indeterminate
170 potential (CHIP), a precancerous condition defined by the presence of expanded leukemogenic
171 mutation that we previously showed to be associated with LTL³⁷; and CAD. Non-hematologic
172 neoplasms were associated with longer LTL [odds ratio (OR) = 1.07, $P = 5.2 \times 10^{-7}$] with
173 additional adjustment for total cholesterol, smoking, blood pressure, BMI, and blood glucose (n
174 = 82,371). In comparison, hematologic neoplasms were associated with shorter LTL (OR = 0.8,
175 $P = 1.8 \times 10^{-14}$). Both non-hematologic and hematologic neoplasms were associated with longer
176 LTL-PGS in EUR (non-hematologic: OR = 1.03, $P = 0.01$; hematologic: OR = 1.08, $P = 3.8 \times 10^{-3}$;
177 $n = 52,685$). CHIP was associated with shorter LTL ($\beta = -0.24$, $P = 4.1 \times 10^{-14}$), as we and
178 others reported before in other datasets^{25,37,38}, with heterogeneity across driver genes (Extended
179 Data Fig. 4). Greater variant allele frequency (AF) of CHIP was robustly associated with shorter
180 LTL ($\beta = -0.014$, $P = 1.9 \times 10^{-11}$). Increased risk of CAD was associated with both measured
181 shorter LTL (OR = 0.85, $P = 6.1 \times 10^{-27}$) and shorter LTL-PGS (OR = 0.95, $P = 1.3 \times 10^{-3}$ in EUR)
182 with the same additional adjustment.

183 **Geographically heterogeneous LTL among U.S. participants**

184 Next, we examined whether LTL varied geographically across the U.S. We calculated the effect
185 estimate of participants' 3-digit ZIP code for LTL, adjusting with age, sex, the first 10 genetic
186 PCs, and sequencing site. Several large cities and surrounding areas showed higher coefficients
187 than others (Fig. 3c). Cluster analysis showed that the West Coast area and Central Midwest area
188 had significantly higher coefficients ($\beta = 0.040$, $P = 0.002$, and $\beta = 0.047$, $P = 0.027$,
189 respectively), while the Southeast area clustered significantly lower coefficients ($\beta = -0.073$, $P =$
190 0.001). The same trend held in state-level analysis (Extended Data Fig. 5a). Additional
191 adjustment for BMI, smoking, and neighborhood deprivation index still resulted in similar
192 heterogeneity (Extended Data Fig. 5b-d). EUR-only analysis, LTL-PGS, and LTL-residual in
193 EUR also yielded similar trends (Extended Data Fig. 5e-g).

194 **Genome-wide association study (GWAS) for common variants in AoU identified 11 novel**
195 **loci**

196 We performed GWAS for LTL using common variants (minor AF > 0.1%, Extended Data Fig.
197 6a-e) with genomic control by linkage disequilibrium score (LDSC) regression intercept³⁹
198 (Supplementary Table 3). We observed non-zero heritability for LTL [0.240 ($P = 1.1 \times 10^{-6}$) in
199 AFR, 0.132 ($P = 3.3 \times 10^{-6}$) in Admixed-American-like population (AMR), and 0.133 ($P =$
200 1.0×10^{-4}) in EUR, Supplementary Table 4]. We found 37 genome-wide significant loci ($P <$
201 5×10^{-8}) in AFR, 26 in AMR, 5 in East-Asian-like population (EAS), and 78 in EUR. Among
202 them, 11 were novel (4 in AFR, 1 in AMR, 6 in EUR, Supplementary Table 5). One of the novel
203 loci was found in EUR with the lead variant (chr3:142485886:C:T, AF = 0.177, $\beta = 0.032$, $P =$
204 9.5×10^{-10}) at an intron of *ATR* in 3q23 (Extended Data Fig. 6f). *ATR* and *ATM* (found in
205 previous GWAS locus at 11q22.3 and gene-based test^{4,25}) are two primary DNA damage
206 response transducers that are crucial in telomere maintenance⁴⁰. *HBB* locus, a significant locus in
207 the previous UKB GWAS⁴ suspected to be an artifact because of the variants near the qPCR
208 control sequence used for LTL measurements, was not significant in any genetic ancestry in
209 AoU.

210 **GWAS Meta-analysis with the UK Biobank (UKB) identified 22 additional novel loci**

211 GWAS in UKB was revised using the previously measured LTL by qPCR⁴ (Supplementary Fig.
212 3a-d) for comparison and meta-analysis with AoU. The genetic correlation between AoU and
213 UKB calculated by LDSC³⁹ was 0.958 ($P = 2.0 \times 10^{-332}$) in EUR. Effect estimates for AoU (β_{AoU})
214 and UKB (β_{UKB}) for lead variants found in AoU were highly correlated ($R^2 = 0.91$), and effect
215 estimate of β_{UKB} for β_{AoU} in linear regression model was 1.19 ($P = 1.7 \times 10^{-83}$, Supplementary Fig.
216 4).

217 We meta-analyzed AoU GWAS with UKB GWAS by genetic ancestries (Extended Data Fig. 7a-
218 d). We found 38 genome-wide significant loci in AFR, 6 in EAS, 207 in EUR, and 2 in South
219 Asian-like population (SAS), of which 3 in AFR, 1 in EAS, and 20 in EUR were novel
220 (Supplementary Table 5). There was no evidence of inflation, with λ_{GC} being 1.0835 for AFR,
221 1.0048 for EAS, and 1.0076 for SAS. Although in EUR, we observed moderately elevated λ_{GC}
222 (1.32), the attenuation ratio by LDSC of 0.045 suggested the contribution of the polygenic nature
223 of LTL (Supplementary Table 6). We performed PoPS⁴¹ to prioritize potentially causal genes
224 with functional plausibility. For example, *GFI1B*, a master transcription factor that is necessary
225 for maintaining hematopoietic stem cell quiescence⁴², was prioritized by PoPS at 9q34.13 locus
226 (Extended Data Fig. 8a). The lead variant chr9:133018743:C:T (nearest gene *GTF3C5*, AF_{EUR} =
227 0.186, $\beta_{\text{EUR}} = -0.015$, $P_{\text{EUR}} = 2.5 \times 10^{-10}$) is in linkage disequilibrium (LD) with
228 chr9:133004155:C:T (rs524137, $R^2_{\text{EUR}} = 0.52$), which is a functionally validated causal variant in
229 GWAS for myeloproliferative neoplasms⁴³. Chr9:133004155:C:T accelerates the cell cycles of
230 hematopoietic stem cells via *GFI1B* suppression, aligning to the association with shorter LTL.
231 Another example at novel locus is *RMI2*, a known component of BLM-TOP3A-RMI complex
232 that suppress alternative lengthening of telomere (ALT)⁴⁴, which was prioritized at 16p13.13

233 locus (lead variant: chr16:11842460:C:T, $AF_{EUR} = 0.639$, $\beta_{EUR} = -0.011$, $P_{EUR} = 2.0 \times 10^{-8}$,
234 Extended Data Fig. 8b).

235 Genes identified by agreement on both distance to lead variants and PoPS scores at the locus
236 were reported to have the highest precision and recall⁴¹. *CKS2*, *PTEN*, and *EXOSC7* were such
237 examples in novel loci. *CKS2* at 9q22.2 (lead variant: chr9:89311173:C:T, $AF_{EUR} = 0.0902$, β_{EUR}
238 $= -0.021$, $P_{EUR} = 1.5 \times 10^{-10}$, Extended Data Fig. 8c) is essential for cell cycle interacting cyclin-
239 dependent kinases⁴⁵. *PTEN* at 10q23.31 (lead variant: chr10:87957355:G:T, $AF_{EUR} = 0.0394$,
240 $\beta_{EUR} = 0.028$, $P_{EUR} = 2.1 \times 10^{-9}$, Extended Data Fig. 8d) is reported to reduce expression of
241 Telomerase^{46,47}. *EXOSC7* at 3p21.31 locus (lead variant: chr3:44976290:A:G, $AF_{EUR} = 0.0917$,
242 $\beta_{EUR} = -0.019$, $P_{EUR} = 1.4 \times 10^{-9}$, Extended Data Fig. 8e) is a member of the EXOSC family,
243 whose other members has been identified in previous LTL GWAS loci^{4,48}. The EXOSC family
244 forms exosome, which contributes to the processing of the template of telomere, human
245 telomerase RNA⁴⁹.

246 Genetic ancestry- and sex-specific loci

247 We identified 3 novel loci in AFR meta-analysis and 1 novel locus in EAS meta-analysis that
248 were not significant in EUR meta-analysis (Supplementary Table 5). For example,
249 chr15:90797341:G:A at 15q26.1 was specific to AFR ($AF_{AFR} = 0.015$, $\beta_{AFR} = -0.15$, $P_{AFR} =$
250 6.3×10^{-11} , $AF < 0.001$ in other genetic ancestries, Fig. 4a and b, Extended Data Fig. 7e), which
251 was located at the intron of *BLM*. *BLM* helps resolve or overcome the G-quadruplex structure
252 formed on the G-rich telomere strand when the telomere replicates⁵⁰. Another example,
253 chr10:109948435:A:G was significant only in AFR ($AF_{AFR} = 0.776$, $\beta_{AFR} = 0.045$, $P_{AFR} =$
254 6.2×10^{-11} , Fig. 4c and d). Though the lead variant is not rare in other genetic ancestries ($AF = 0.15-$
255 0.51), the effect estimates were smaller, which was consistent in a previous multi-ancestry
256 GWAS for LTL in NHLBI Trans-Omics for Precision Medicine (TOPMed²⁴, Supplementary
257 Table 7).

258 We assessed if there was heterogeneity between sexes for genomic predispositions. Sex-stratified
259 GWAS showed high genetic correlations between sexes (0.96 , $P = 7.0 \times 10^{-404}$ in EUR,
260 Supplementary Table 8). Heterogeneity test in EUR showed that one of the previously reported
261 loci at Xq28 was only significant in females, which was consistent in other genetic ancestries
262 (Fig. 4e and f). The lead variant at this locus was chrX:152767196:C:A ($AF_{Female} = 0.15$, β_{Female}
263 $= 0.066$, $P_{Female} = 4.1 \times 10^{-80}$; $AF_{Male} = 0.15$, $\beta_{Male} = 0.0046$, $P_{Male} = 0.093$; $P_{Sex-heterogeneity} =$
264 2.4×10^{-43}), a missense variant of *MAGEA6*.

265 Multi-ancestry GWAS meta-analysis identified 3 additional novel loci

266 Finally, multi-ancestry meta-analysis was performed using MR-MEGA with the first 3 PCs of
267 genetic ancestry (Extended Data Fig. 9a and b). There was no evidence of inflation with λ_{GC}
268 being 1.086, yielding more power than previous multi-ancestry GWAS meta-analysis with
269 comparable sample size⁵¹ (Extended Data Fig. 9c). We found 184 independent loci, of which 13
270 were novel, and 3 were not found in genetic ancestry specific analyses. *MUS81* prioritized by

271 PoPS at novel 11q13.1 locus (lead variant chr11:65814557:A:G, AF = 0.596, $P = 6.4 \times 10^{-9}$,
272 Extended Data Fig. 9d) is required for telomere recombination via ALT⁵². *AXINI* prioritized at
273 novel 16p13.3 locus (lead variant chr16:797597:T:C, AF = 0.297, $P = 3.6 \times 10^{-10}$, Extended Data
274 Fig. 9e) is a regulator of Wnt signaling⁵³, which is a known contributor to telomere
275 maintenance^{54,55}.

276 Overall, our GWASs and meta-analyses identified 199 out of 252 (78.9%) previously reported
277 GWAS loci. The majority of novel loci (28/36, 77.8%) were directionally consistent with
278 previous multi-ancestry GWAS in TOPMed²⁴. We found 25 subtelomeric regions (within 2 Mb
279 from telomeres) with significant loci out of 46 subtelomeric regions (54.3%), which may
280 indicate the mechanisms that subtelomeric regions control global telomere length, such as
281 TERRA⁵⁶. The locuszoom plots of all GWAS meta-analysis loci were shown in Supplementary
282 Fig. 5 with available FINEMAP⁵⁷ and PoPS annotations.

283 **Rare variant association study (RVAS) identified 7 novel genes**

284 To assess the contribution of the rare variations and direct identification of causal genes to LTL,
285 we performed gene-based aggregation tests using deleterious coding variants with alternative AF
286 below 0.1% (Method). RVAS detected 26 genes significantly ($P < 2.5 \times 10^{-6}$) associated with
287 LTL, of which 7 were not detected by previous RVASs^{4,25} (Fig. 5a, Supplementary Table 9).

288 Four novel genes, *TGS1*, *RPA1*, *RFWD3*, and *ZSCAN5B*, were located in common variant
289 GWAS loci (Supplementary Fig. 6a-d) but were not described in previous RVAS^{4,25}, which all
290 had evidence of involvement in telomere biology. *TGS1* forms the 2,2,7-trimethylguanosine cap
291 structure at the human telomerase RNA 5' end, which recruits telomerase to telomeres and
292 engages Cajal bodies in telomere maintenance⁵⁸. *RPA1* binds to telomeres, and gain-of-function
293 mutations in *RPA1* cause short telomeres⁵⁹. *RFWD3* and *ZSCAN5B* play roles in DNA damage
294 response^{60,61}.

295 Three novel genes, *TERF2IP*, *RBM7*, and *COIL*, were not located in common variant GWAS
296 loci (Supplementary Fig. 6e-g). *TERF2IP* encodes RAP1, the last component of the Shelterin
297 complex not found in previous GWAS⁶². *RBM7* is a component of the nuclear exosome targeting
298 (NEXT) complex that processes telomerase RNA⁴⁹. *COIL*, which encodes coilin, is debated
299 whether it is involved in telomere maintenance. Despite coilin knockout mice and human cells
300 not showing defects in telomere maintenance, a number of indirect evidence suggest its
301 involvement⁶³. Our finding provides orthogonal evidence that coilin is involved in telomere
302 maintenance.

303 All telomerase component genes found in RVAS were associated with shorter LTL (Fig. 5b).
304 This is consistent with the fact that we primarily included putative loss-of-function or deleterious
305 missense variants in RVAS. On the other hand, all CST component genes were associated with
306 longer LTL, which is consistent with the function of CST to suppress telomerase⁶⁴. All the
307 components of the Shelterin complex, including *POT1*, were consistently associated with longer

308 LTL. Though the Shelterin complex protects the telomere from instability⁶⁵, loss of function
309 mutations in *POT1* elongates telomeres with unknown mechanisms¹⁶. Genes related to thymidine
310 metabolism showed the effects in both directions. *TYMS* and *TK1* were associated with shorter
311 LTL, and *SAMHD1* was associated with longer LTL. These effects were directionally consistent
312 with findings in the knockout experiments of these genes⁶⁶.

313 We found six CHIP-related driver genes associated with LTL. *PPM1D*, *ASXL1*, *DNMT3A*,
314 *SF3B1*, and *TET2* were associated with shorter LTL; however, as CHIP is associated with
315 shorter LTL, we could not exclude that these associations were derived from the residual somatic
316 mutations in the genotypes. *SRSF2*, also a known CHIP driver gene, was associated with longer
317 LTL. CHIP might also influence this association since large clones of *SRSF2* CHIP are
318 associated with longer LTL²⁵, and CHIP with small clones was likely excluded from the
319 genotype call.

320 **Polygenic score (PGS) improved the predictive performance in AFR**

321 We assessed the incremental contribution of increasing genetic ancestry diversity and sample
322 size by meta-analysis on the performance of PGS predictive performance. We re-ran GWAS in
323 AoU, excluding validating ($n = 2,000$) and testing ($n = 8,000$) individuals from both EUR and
324 AFR and derived PGS. Compared to PGS derived from UKB alone (partial R^2 : 0.00161 in AFR,
325 0.0712 in EUR), PGS derived from the meta-analysis of UKB and AoU improved the predictive
326 value with prominent improvement in AFR (partial R^2 : 0.0425 in AFR, 0.0769 in EUR,
327 Extended Data Fig. 10, Supplementary Table 10). The partial R^2 in AFR was higher in PGS
328 derived from the AFR meta-analysis ($n = 51,895$, partial $R^2 = 0.0425$) than PGS derived from
329 the EUR meta-analysis encompassing over 10 times more samples ($n = 548,812$, partial $R^2 =$
330 0.0319) suggesting the importance of the diversity in the derivation dataset.

331

332 **Discussion**

333 In this study, we estimated LTL in diverse AoU participants via blood-based WGS and evaluated
334 associations with various health-related traits and diseases/conditions. Leveraging diverse
335 genetic ancestries in AoU, we observed that these associations were highly heterogeneous across
336 genetic ancestries and sexes. We further described that the variance of LTL was geographically
337 heterogeneous across the U.S. Lastly, meta-analysis for common variant GWAS and RVAS with
338 UKB revealed 36 novel loci and 7 novel genes, which also uncovered the existence of genetic
339 ancestry- and sex-specific loci.

340 AoU provides a unique opportunity to evaluate LTL-trait associations across diverse genetic
341 ancestries in a consistent platform, revealing heterogeneities that have been difficult to detect in
342 other datasets. Since qPCR can be affected by the variants at the control sequence⁴, which
343 potentially differs across genetic ancestry, our approach using WGS data is advantageous using
344 whole genome as the reference to compare across genetic ancestries. The heterogeneous

345 associations between LTL and traits indicate some differences among genetic ancestries and
346 sexes may modify the associations between traits and LTL. Further investigation into the
347 mechanisms of heterogeneity may enable novel insights regarding healthy aging across contexts.

348 The variation in LTL distribution across the U.S. aligns with general population health trends,
349 including life expectancy⁶⁷ and cardiometabolic risk factors, such as BMI⁶⁸, diabetes⁶⁹,
350 hypertension, smoking, and poor diet⁷⁰. Prior research has shown that the health outcomes (e.g.,
351 life expectancy, years potential life lost, diabetes, fair or poor health), access to clinical care
352 (e.g., uninsured rates), health behaviors (e.g., smoking, excessive drinking, obesity), and social
353 and economic factors tend to be more favorable in urban areas compared to rural areas in the
354 U.S., despite rural area having more favorable physical environment characteristics (e.g., better
355 air quality and housing availability)⁷¹. The overlapping geographical heterogeneity in LTL and
356 these traits indicates a potential contextual role of LTL in general health.

357 We found genetic ancestry- and sex-specific genetic predispositions for LTL, though the
358 majority of the associated loci were shared across these backgrounds. Despite the much smaller
359 sample sizes in those dissimilar to EUR, we found several genetic ancestry-specific variants
360 associated with LTL only in those genetic ancestries, highlighting the critical need for more
361 diverse representation in genetic studies. Ongoing initiatives to expand genomic data across
362 diverse genetic ancestries, such as those spearheaded by AoU and others, along with recent
363 development of methods tailored for multi-ancestry genomic studies, will further genetic
364 discovery and address the disparities in human genetic studies. In addition, the consistent and
365 differential genetic associations across genetic ancestries and sexes implicate important
366 generalizable insights about LTL regulation.

367 Important limitations should be considered in the interpretation of these findings. First, in the
368 present study, the measured LTL is the average of all the chromosomes and cell types, while
369 LTL has heterogeneity across chromosomes⁷². Long-read sequencing-derived WGS data at the
370 population scale will add further granularity to these analyses. Second, considering LTL is
371 associated with a number of health-related traits, the findings in AoU have a limitation for
372 generalizability outside the U.S.

373 In conclusion, this study revealed phenomic, genomic, and geographic heterogeneity for LTL,
374 emphasizing that context influences both the distribution and phenotypic associations of LTL.
375 Further understanding of the mechanisms underlying these factors aims to facilitate healthy
376 aging across the diverse communities in the U.S.

377 **Methods**

378 **Study cohorts**

379 The *All of Us* Research Program (AoU) aims to engage a longitudinal cohort of one million or
380 more U.S. participants, with a focus on including populations that have historically been under-
381 represented in biomedical research. Detailed protocol of the AoU cohort and its genomic data
382 have been described previously^{73,74}. Briefly, adults 18 years and older who have the capacity to
383 consent and reside in the U.S. or a U.S. territory at present were eligible. Informed consent for
384 all participants was conducted in person or through an eConsent platform that includes primary
385 consent, HIPAA Authorization for Research use of EHRs and other external health data, and
386 Consent for Return of Genomic Results. The protocol was reviewed by the Institutional Review
387 Board (IRB) of the AoU Research Program. The AoU IRB follows the regulations and guidance
388 of the NIH Office for Human Research Protections for all studies, ensuring that the rights and
389 welfare of research participants are overseen and protected uniformly. The details of the cohort
390 construction were summarized in Supplementary Fig. 1. Briefly, we inspected 245,394 whole
391 genome sequence (WGS) data in AoU version 7 release. We excluded flagged samples for poor
392 sequencing quality by AoU (n = 549), genotyping missingness > 0.01 (n = 395), lacking age
393 information (n = 26), and genetically undetermined sex (n = 1,930) to construct a cohort of
394 242,494 participants included in our analysis. For epidemiologic studies, we further excluded
395 outliers (> 20 median absolute deviations) for principal components (PCs) calculated from
396 sequencing depth (NGS-PCs, n = 442). For genomic studies, we further excluded < 0.75 for
397 random forest probabilities for the largest 5 population groups [African-like population (AFR),
398 Admixed American-like population (AMR), East Asian-like population (EAS), European-like
399 population (EUR), and South Asian-like population (SAS)] in AoU (n = 19,511), missing
400 genotyping array information (n < 21, According to AoU publishing policy, numbers below 21
401 cannot be published. Precise counts are not calculable due to overlapping samples across
402 multiple QC metrics.), and outliers (> 20 median absolute deviation) for NGS-PCs (n = 261).

403 The UK Biobank (UKB) is a population-based cohort of >500,000 UK adult residents recruited
404 between 2006 and 2010 and followed prospectively via linkage to national health records⁷⁵.
405 Secondary analyses of the UKB data under Application 7089 were approved by the
406 Massachusetts General Hospital IRB. At the baseline study visit, consented participants
407 underwent phlebotomy and provided detailed information about medical history and medication
408 use. In the present study, the UKB cohort included adults aged 40 to 70 years at blood draw with
409 available genotyping array or whole exome sequences (WES)⁷⁶. We used genotyping array for
410 genome-wide association study for common variants (N = 488,188) and WES for rare variant
411 association study (N = 452,929). We excluded samples with consent retraction, excess
412 heterogeneity, sex discordance, or missingness/heterogeneity/outliers in the genotype, as
413 summarized in Supplementary Fig. 1.

414 **Leukocyte telomere length (LTL) Estimation**

415 TelSeq²⁶ was used in a previous genome-wide association study for WGS-derived LTL^{24,25},
416 while more recent algorithms for WGS-derived LTL estimation have been published, including
417 Telomerecat⁷⁷. We compared the two methods using 1,000 random participants in UKB with
418 available quantitative polymerase chain reaction (qPCR) measurements of LTL and WGS for the
419 same individuals. TelSeq had better agreement with qPCR with similar R^2 to previous report²⁵
420 (Extended Data Fig. 1a). Thus, we estimated the LTL using TelSeq²⁶ with available WGS
421 CRAM files in AoU. To align with the computational demand on the AoU workbench system,
422 we modified the TelSeq integrating htslib-1.18⁷⁸ to enable direct CRAM file processing, parallel
423 processing across the cores, and streaming processing from Google Cloud Storage, which
424 achieved 4 times better efficiency (Extended Data Fig. 1c and d). The estimated LTL was
425 verified as identical to the original software in the randomly selected 1,000 European WGS
426 CRAM files in UKB and AoU (Extended Data Fig. 1b). The parameter k for TelSeq was set to
427 10, in line with the previous reports^{24,25}.

428 We adjusted the estimated telomere length with sequencing depth as described before²⁴. Briefly,
429 we performed mosdepth v0.3.5²⁷ on each CRAM file to calculate the sequencing depth in 1,000-
430 base pair bins across the genome. Using the resultant depth information, we calculated 200 PCs
431 using NGS-PCA (<https://github.com/PankratzLab/NGS-PCA>). NGS-PCA was modified to
432 enable stream processing from Google Cloud Storage to deal with large samples on the AoU
433 Workbench system. Due to the limitation of the computing resource available in the AoU
434 workbench, the PCs were separately calculated within each genetic ancestry for GWAS studies
435 and within each sequencing site for epidemiological studies. The first 50 PCs were verified
436 identical to the original software output using 100 random samples in AoU. We used PCs
437 explaining more than 0.1% of the total variance calculated to residualize the LTL
438 (Supplementary Fig. 7). We excluded samples with extreme outliers (over 20 median absolute
439 deviations in each group) with used NGS-derived PCs. The number of PCs used for each group
440 and the number of excluded samples are shown in Supplementary Table 11. LTL was
441 residualized by NGS-PCs to obtain relative LTL adjusted for sequencing heterogeneity. This
442 adjustment increased the power to detect previously known associations with genomic variation
443 and suppressed spurious associations (Extended Data Fig. 1e and f).

444 **Epidemiology**

445 Phenotypes (outcome) were tested for associations with LTL (exposure) by linear regression
446 model (continuous traits) or logistic regression model (binary traits) with adjustment for age,
447 sex, first ten genetic PCs, and sequencing site. Analyses with cases less than 21 were excluded.
448 Phenotype definitions were listed in Supplementary Table 12, unless described below.

449 *Wearable device data*

450 Details of wearable device data in AoU were described previously⁷⁹. Briefly, Participants who
451 provided primary consent to be part of the AoU and share EHR data had an opportunity to

452 provide their data from wearable devices under the Bring Your Own Device program.
453 Participants connected their own Fitbit device account with the AoU Participant Portal and
454 agreed to share their complete data on their device over all time, including previous data, not just
455 recent data. A participant could stop sharing their data at any time. Participants' data had direct
456 identifiers removed, and all datetime fields were subjected to date shifting by a random number
457 between 1 and 365 days in accordance with approved AoU privacy policies. We analyzed the
458 median of steps per day and the median sleep duration per day.

459 *Neighborhood deprivation index*

460 Neighborhood deprivation indices⁸⁰ for each 3-digit prefix of ZIP codes were calculated by AoU
461 and accessible in the controlled tier. Briefly, a neighborhood deprivation index for each census
462 tract in the United States was calculated based on a principal component analysis of six different
463 2015 American Community Survey measures (fraction of households receiving public assistance
464 income or food stamps or Supplemental Nutrition Assistance Program (SNAP) participation in
465 the past 12 months, the fraction of population 25 and older with the educational attainment of at
466 least high school graduation includes GED equivalency, median household income in the past 12
467 months in 2015 inflation-adjusted dollars, the fraction of population with no health insurance
468 coverage, the fraction of population with income in past 12 months below poverty level, and
469 fraction of houses that are vacant); rescaling and normalizing forces the index to range from 0 to
470 1, with a higher index being more deprived.

471 *Phecode*

472 We ascertained phenome-wide clinical outcomes based on phecode^{33,34}
473 (<https://www.phewascatalog.org/phecodes>, version 1.2) using ICD-9/ICD-10 codes curated from
474 the AoU electronic health records. For a given subject, if any ICD codes from the inclusion
475 criteria of a phecode were recorded, the subject was classified as a case. Conversely, if none of
476 these ICD codes were recorded, the subject was classified as a control. If the number of cases is
477 greater than 10, association with LTL was tested by logistic regression model, and heterogeneity
478 of the association was tested by Cochran's Q test, both with Bonferroni correction.

479 *Hematologic cancer, non-hematologic cancer, clonal hematopoiesis of indeterminate potential* 480 *(CHIP), and coronary artery disease (CAD)*

481 Hematologic cancer, non-hematologic cancer, and CAD were defined by any of the recorded
482 International Classification of Diseases (ICD9 and ICD10), Current Procedural Terminology 4
483 (CPT4), Healthcare Common Procedure Coding System (HCPCS), and Diagnosis Related Group
484 (DRG) codes, and SNOMED terminology listed in Supplementary Tables 13-15. CHIP is
485 ascertained in AoU as described before⁸¹. Briefly, Mutect2⁸² detected the putative somatic
486 mutations using WGS data. Mutations with minimal allelic depth of less than 5 were excluded to
487 reduce false positives. Then, the putative variants were cross-referenced with the previously
488 identified CHIP-related variants⁸³.

489 **Geographic analysis**

490 Coefficients for LTL were calculated for each 3-digit prefix of ZIP codes by the linear regression
491 model, adjusting with age, sex, first 10 genetic PCs, and sequencing site. The ZIP codes starting
492 with 000 were excluded from the analyses (n = 147). The individuals with discordant state and
493 ZIP code information were also excluded from the analyses. For cluster analysis, the coefficient
494 was weighted by inverse variance and analyzed with SaTScan version 10.1.3⁸⁴ with a 1,000-
495 kilometer restriction of cluster size. Figures were plotted using R package sf⁸⁵ and ggplot2⁸⁶,
496 excluding groups with less than 21 participants in each granularity to align with the publishing
497 policy of AoU. The shape files and population information were downloaded from the U.S.
498 Census Bureau (<https://www.census.gov/>).

499 **Genetic ancestry ascertainment**

500 Genetically similar population groups were predicted by Data and Research Center (DRC) using
501 random forest probability > 0.75 calculated with the first 16 genetic PCs. Briefly, 151,159 high-
502 quality sites, which can be called accurately in both the training set (Human Genome Diversity
503 Project and 1000 Genomes)^{87,88} and target data (AoU short read WGS), were identified by
504 autosomal and bi-allelic single nucleotide variants only, allele frequency (AF) > 0.1%, call rate >
505 99%, and linkage disequilibrium (LD)-pruned with a cutoff of $R^2 = 0.1$ similarly with
506 gnomAD⁸⁹. Genetic PCs were then derived using the hwe_normalized_pca in Hail at this high-
507 quality variant sites. A random forest classifier was trained on the training set using variants
508 obtained from gnomAD on the autosomal exons of protein-coding transcripts in GENCODE
509 v42⁹⁰. The AoU samples were projected into the PCA space of the training data, and the
510 classifier was applied.

511 **Genotype-based sample filtering**

512 All the samples flagged by AoU CDR and GC due to genotype heterogeneity were excluded
513 from all analyses (n = 549). Briefly, eight median absolute deviations away from the median
514 residuals in any of the following metrics were excluded after residualization by the first 16
515 genetic PCs: number of deletions, number of insertions, number of single nucleotide
516 polymorphisms, number of variants not present in gnomAD 3.1, insertion to deletion ratio,
517 transition to transversion ratio, and heterozygous to homozygous ratio (single nucleotide
518 polymorphisms and Indel separately). We further excluded samples with variant calling
519 missingness over 5%, without information on genetically estimated sex ploidy by the DRAGEN
520 pipeline, and missing in the array genotype file provided by AoU at the time of analysis
521 (December 2023).

522 **Genotype and variant quality control**

523 *Genotyping array*

524 We use array-based genotypes provided by AoU for the Regenie Step 1 and by UKB for both
525 Steps 1 and 2. Variants with missingness > 1%, minor AF < 1%, and Hardy-Weinberg
526 Equilibrium mid-p adjusted p-value < 1×10^{-6} were excluded in each genetic ancestry group.

527 Variants were then pruned with variant window 1,000 kb, variant sliding window 100 kb, and R^2
528 0.5. In addition, we excluded variants located in high linkage disequilibrium regions⁹¹.

529 *WGS in AoU*

530 We used the WGS-based genotype provided by AoU for the Regenie Step 2. AoU CDR and GC
531 marked genotypes that were low-quality or failed allele-specific variant quality score
532 recalibration calculated by GATK⁹². We filtered out those genotypes in our analysis and split
533 multi-allelic variants into biallelic by Hail (<https://github.com/hail-is/hail>). Variants were filtered
534 out by PLINK2.00 if missingness > 0.05 or Hardy-Weinberg Equilibrium $P < 1 \times 10^{-6}$ with mid-p
535 adjustment in each genetic ancestry. We further excluded variants located in low-complexity
536 regions and segmental duplications with over 95% similarity. The numbers of included variants
537 are listed in Supplementary Table 16.

538 *WES in UKB*

539 For genotype-level quality control, we first used Hail's `split_multi_hts` function to divide
540 multiallelic sites and filtered out low-quality genotypes; genotyping quality ≤ 20 , depth ≤ 10 or $>$
541 200, $(DP_{\text{Reference}} + DP_{\text{Alternate}})/(DP_{\text{Total}}) > 0.9$ and $DP_{\text{Alternate}}/DP_{\text{Total}} > 0.2$ for heterozygous
542 genotypes, $DP_{\text{Alternate}}/DP_{\text{Total}} > 0.9$ for alternate homozygous genotypes. This process retained
543 26,645,535 variants in 454,756 samples. We excluded 6,289,813 variants due to high
544 missingness ($>10\%$), Hardy-Weinberg deviation ($P_{\text{HWE}} < 1 \times 10^{-15}$), or low-complexity regions,
545 leaving 20,355,722 variants.

546 **GWAS for common variant**

547 We followed the previously recommended fully adjusted two-step procedure⁹³. We residualized
548 the estimated LTL by age, sex (imputed from genotype by DRAGEN pipeline provided by AoU
549 Genome Center [GC] and DRC), the first 10 PCs calculated from genotype (provided by AoU
550 GC and DRC), the PCs from NGS-PCA²⁴ (<https://github.com/PankratzLab/NGS-PCA>), and
551 sequencing site in each genetic ancestry group. We included all the NGS PCs, explaining at least
552 0.1% of the total calculated variance (the number of PCs included is shown in Supplementary
553 Table 11). Regenie⁹⁴ Step 1 was performed with blocks of sizes 1,000 for LD computation,
554 adjusting for age, sex, first 10 genetic PCs, sequencing site, and NGS-PCs explaining $> 0.1\%$
555 variance. LTL was rank normalized using `--apply-rint` option. Regenie Step 2 was performed by
556 adjusting for the same variable in Step 1 for the WGS-based genotype with larger than 0.1% of
557 minor AF. LD score regression was performed using 1000G WGS-derived LD scores to assess
558 inflation (Supplementary Table 3) and calculate the genetic correlation in EUR between AoU
559 and UKB. We applied genomic control by multiplying the standard error by the square root of
560 the LD Score regression intercept and recalculated P values accordingly. We defined the
561 genome-wide significance threshold as 5×10^{-8} . An independent locus was defined if the
562 significant variants were more than 1 Mb apart. Novel locus was defined if the lead or sentinel
563 variants reported in the previous 17 GWAS studies^{4,19,21,24,25,48,51,95-104} (listed in Supplementary
564 Table 17) were more than 1 Mb apart from all the significant variants in the locus. Additionally,

565 we investigated the summary statistics from LTL GWAS in UKB and revised the significant loci
566 to align the definition of significance in AoU. We excluded the loci that overlapped with the
567 aforementioned definition with these summary statistics from novel definitions, in addition to
568 excluding previously reported sentinel variants in UKB⁴.

569 **GWAS Meta-analysis with UKB**

570 We performed GWAS for each genetic ancestry (random forest probability > 0.75 using genetic
571 PCs) with NHLBI Trans-Omics for Precision Medicine (TOPMed) imputed genotype aligned to
572 GRCh38, which aligned the method with the GWAS in AoU. We used GWAMA¹⁰⁵ in each
573 genetic ancestry group and filtered out the variants supported by only one cohort. We excluded
574 the variants with high heterogeneity ($P < 10^{-6}$) from the locus definition, which excluded *HBB*
575 locus in line with the previously suspected artifact at this locus derived from the qPCR control
576 used in UKB⁴. LD Score regression intercept and ratio were calculated to confirm the controlled
577 genome-wide test statistics (Supplementary Table 6). We further performed a multi-ancestry
578 meta-analysis using MR-MEGA¹⁰⁶ with three PCs as previously performed¹⁰⁷.

579 **Rare variant association study**

580 We used the same condition for Regenie Step1 as the common variant association study. Step 2
581 was performed with alternative AF less than 0.1%. To prioritize deleterious missense variants,
582 we generated a missense score using 30 functional annotations available in dbNFSP (version
583 4.2), as previously described¹⁰⁸. Briefly, we predicted the deleteriousness of missense variants
584 using 30 (MetaRNN_pred, SIFT_pred, SIFT4G_pred, Polyphen2_HDIV_pred,
585 Polyphen2_HVAR_pred, LRT_pred, MutationTaster_pred, MutationAssessor_pred,
586 FATHMM_pred, PROVEAN_pred, VEST4_rankscore, MetaSVM_pred, MetaLR_pred, M-
587 CAP_pred, REVEL_rankscore, MutPred_rankscore, MVP_rankscore, MPC_rankscore,
588 PrimateAI_pred, DEOGEN2_pred, BayesDel_addAF_pred, BayesDel_noAF_pred,
589 ClinPred_pred, LIST-S2_pred, CADD_phred, DANN_rankscore, fathmm-MKL_coding_pred,
590 fathmm-XF_coding_pred, Eigen-phred_coding, Eigen-PC-shred_coding) annotations and
591 computed the proportion of deleterious predictions (missense score). We then created masks for
592 aggregation tests using predicted loss-of-function variants and missense variants with missense
593 scores higher than 0.6. Variants were annotated using VEP version 105. Multi-ancestry meta-
594 analyses were performed using GWAMA with a fixed effect inverse variance weighted method.

595 **LD-score regression**

596 Genetic correlations and LD Score regression intercept and ratio were calculated by using LDSC
597 software version 1.0.1³⁹. LD scores were computed using the 1000 Genomes Project phase 3
598 release data and variants in the HapMap3 project¹⁰⁹ with minor allele count ≥ 5 .

599 **Polygenic prioritization of candidate causal genes**

600 We implemented PoPS (v0.2)⁴¹, a similarity-based gene prioritization method designed to
601 leverage the full genome-wide signal to nominate causal genes independent of methods utilizing

602 GWAS data proximal to the gene. PoPS leverages polygenic enrichments of gene features,
603 including cell-type-specific gene expression, curated biological pathways, and protein-protein
604 interaction networks to train a linear model to compute a PoPS score for each gene. We used the
605 EUR reference panel for multi-ancestry summary statistics, while genetic ancestry-specific
606 analyses leveraged genetic ancestry-specific reference panels. The analysis was limited to
607 autosomes.

608 **Finemapping**

609 LD-informed statistical finemapping by FINEMAP (version 1.4.2)⁵⁷ was conducted using the
610 results from genetic ancestry-wise meta-analysis with LD information with matched genetic
611 ancestry in AoU. Finemapping was restricted to the variants with $P < 0.05$ to reduce the number
612 of variants included. The LD matrices were computed using WGS data in AoU with LDstore2
613 (version 2.0)⁵⁷ software. Finemapping was conducted by FINEMAP software using default prior
614 probability and other conditions except for using a maximum number of causal variants as 10.
615 We used marginal posterior inclusion probability as a measure of causal probability of the
616 variants. We excluded loci detected in the human major histocompatibility complex region and
617 chromosome X from the finemapping.

618 **Polygenic score (PGS)**

619 For epidemiological analyses, we calculated PGS in EUR in AoU. Variant weights were
620 calculated by GWAS in EUR in UKB using LDpred2¹¹⁰ software. We selected the best
621 parameters using randomly selected 2,000 individuals from EUR in AoU, which were excluded
622 from the subsequent analyses. PGS for the rest of EUR individuals in AoU were computed using
623 PLINK2 software.

624 The performance of PRS was evaluated by the partial R^2 .

$$625 \quad \text{Partial } R^2 = \frac{R^2_{full\ model} - R^2_{reduced\ model}}{1 - R^2_{reduced\ model}}$$

626 The model was adjusted by age, age², sex, the first 10 genetic PCs, and sequencing site.

627 For the performance evaluation after meta-analysis, we conducted GWAS in the AoU cohort
628 separately in AFR and EUR, leaving 10,000 randomly selected individuals in each genetic
629 ancestry to avoid sample overlap. We then meta-analyzed these results with those from the UKB
630 GWAS for respective genetic ancestries, creating meta-analysis results. The weights for
631 polygenic scoring were derived from this genetic ancestry-specific meta-analysis and optimized
632 using LDpred2¹¹⁰ software. PGS for the holdout samples were computed using PLINK2
633 software. We selected the best parameters using randomly selected 2,000 individuals from
634 holdout individuals and tested performance on the remaining 8,000 holdout individuals. The
635 performance of PRS was evaluated by the partial R^2 as described above. The parameters selected

636 and performance metrics for each PGS were summarized in Supplementary Table 10. The
637 distribution of original PGSs before standardization is shown in Supplementary Fig. 8.

638 **Heritability estimation**

639 We performed GCTA GREML¹¹¹ (GCTA version 1.94.2) using 10,000 random unrelated
640 samples at most in each genetic ancestry group with variants minor AF > 1%. The model was
641 adjusted with the same covariates included in the GWAS studies.

642 **Software**

643 FINEMAP 1.4.2, GCTA version 1.94.2, GWAMA ver. 2.2.2, Hail 0.2, LDSC v1.0.1, LDstore
644 2.0, MAGMA v1.10, mosdepth v0.3.5, MR-MEGA ver. 0.2, NGS-PCA v.0.0.2 (modified),
645 PLINK 2.00 (Stable beta 7, 16 Jan), PoPS v0.2, R 4.2 (R packages: ggplot2 version 3.5.1,
646 locuszoomr version 0.3.5, metafor version 3.8-1, sf version 1.0-15, qqman version 0.1.9),
647 Regenie v3.4, SaTScan version 10.1.3, TelSeq v0.0.2 (modified).

648 **Acknowledgment**

649 We acknowledge the studies and participants who provided biological samples and data for AoU
650 and UKB. UKB Resource was used under application number 7089. Secondary use of the UKB
651 data was approved by the Massachusetts General Hospital institutional review board
652 (2021P002228). T.N. is supported by the National Heart Lung Blood Institute (K99HL165024).
653 S.K. is supported by the National Heart Lung Blood Institute (K99HL169733). A.P.P is
654 supported by the National Heart Lung Blood Institute (K08HL168238). P.N. is supported by the
655 National Heart Lung Blood Institute (R01HL168894).

656 **Data Availability**

657 GWAS summary statistics generated in this study will be publicly available at Cardiovascular
658 Disease Knowledge Portal (<https://cvd.hugeamp.org/>) upon publication. The estimated LTL will
659 be returned to AoU upon publication. The genotypes and phenotypes of UKB and AoU
660 participants are available by application to the UKB ([https://www.ukbiobank.ac.uk/register-
661 apply/](https://www.ukbiobank.ac.uk/register-apply/)) and AoU (<https://allofus.nih.gov/>), respectively. The previously published GWAS
662 summary statistic for LTL in UKB (<https://figshare.com/s/caa99dc0f76d62990195>) and meta-
663 analysis (<https://figshare.com/s/f6de1a56ad7c448c1f4c>) are publicly available. The previously
664 published full GWAS summary statistics for LTL in TOPMed are available upon application on
665 dbGap (phs001974).

666 **Code Availability**

667 Modified TelSeq and NGS-PCA will be available in GitHub upon publication. The codes used
668 for the standard analyses will be available at Zenodo upon publication.

669 **Competing interest**

670 P.N. reports research grants from Allelica, Amgen, Apple, Boston Scientific, Genentech / Roche,
671 and Novartis, personal fees from Allelica, Apple, AstraZeneca, Blackstone Life Sciences,
672 Creative Education Concepts, CRISPR Therapeutics, Eli Lilly & Co, Esperion Therapeutics,
673 Foresite Capital, Foresite Labs, Genentech / Roche, GV, HeartFlow, Magnet Biomedicine,
674 Merck, Novartis, TenSixteen Bio, and Tourmaline Bio, equity in Bolt, Candela, Mercury,
675 MyOme, Parameter Health, Preciseli, and TenSixteen Bio, and spousal employment at Vertex
676 Pharmaceuticals, all unrelated to the present work.

677 References

- 678 1. López-Otín, C., Blasco, M. A., Partridge, L., Serrano, M. & Kroemer, G. The hallmarks of aging. *Cell*
679 **153**, 1194–1217 (2013).
- 680 2. Vaiserman, A. & Krasnienkov, D. Telomere length as a marker of biological age: State-of-the-art, open
681 issues, and future perspectives. *Front. Genet.* **11**, 630186 (2020).
- 682 3. Haycock, P. C. *et al.* Leucocyte telomere length and risk of cardiovascular disease: systematic review
683 and meta-analysis. *BMJ* **349**, g4227 (2014).
- 684 4. Codd, V. *et al.* Polygenic basis and biomedical consequences of telomere length variation. *Nat. Genet.*
685 **53**, 1425–1433 (2021).
- 686 5. Arsenis, N. C., You, T., Ogawa, E. F., Tinsley, G. M. & Zuo, L. Physical activity and telomere length:
687 Impact of aging and potential mechanisms of action. *Oncotarget* **8**, 45008–45019 (2017).
- 688 6. Crous-Bou, M., Molinuevo, J.-L. & Sala-Vila, A. Plant-rich dietary patterns, plant foods and nutrients,
689 and telomere length. *Adv. Nutr.* **10**, S296–S303 (2019).
- 690 7. James, S. *et al.* Sleep duration and telomere length in children. *J. Pediatr.* **187**, 247-252.e1 (2017).
- 691 8. Vyas, C. M. *et al.* Telomere length and its relationships with lifestyle and behavioural factors: variations
692 by sex and race/ethnicity. *Age Ageing* **50**, 838–846 (2021).
- 693 9. Bountziouka, V. *et al.* Modifiable traits, healthy behaviours, and leukocyte telomere length: a
694 population-based study in UK Biobank. *Lancet Healthy Longev.* **3**, e321–e331 (2022).
- 695 10. Shalev, I. *et al.* Stress and telomere biology: a lifespan perspective. *Psychoneuroendocrinology* **38**,
696 1835–1842 (2013).
- 697 11. Surtees, P. G. *et al.* Life stress, emotional health, and mean telomere length in the European Prospective
698 Investigation into Cancer (EPIC)-Norfolk population study. *J. Gerontol. A Biol. Sci. Med. Sci.* **66**, 1152–
699 1162 (2011).
- 700 12. Hanssen, L. M., Schutte, N. S., Malouff, J. M. & Epel, E. S. The relationship between childhood
701 psychosocial stressor level and telomere length: A meta-analysis. *Health Psychol. Res.* **5**, 6378 (2017).
- 702 13. Epel, E. S. *et al.* Accelerated telomere shortening in response to life stress. *Proc. Natl. Acad. Sci. U. S. A.*
703 **101**, 17312–17315 (2004).
- 704 14. Telomeres Mendelian Randomization Collaboration *et al.* Association between telomere length and risk
705 of cancer and non-neoplastic diseases: A Mendelian randomization study. *JAMA Oncol.* **3**, 636–651
706 (2017).
- 707 15. Fernández García, M. S. & Teruya-Feldstein, J. The diagnosis and treatment of dyskeratosis congenita: a
708 review. *J. Blood Med.* **5**, 157–167 (2014).
- 709 16. DeBoy, E. A. *et al.* Familial clonal hematopoiesis in a long telomere syndrome. *N. Engl. J. Med.* **388**,
710 2422–2433 (2023).
- 711 17. Blackburn, E. H., Epel, E. S. & Lin, J. Human telomere biology: A contributory and interactive factor in
712 aging, disease risks, and protection. *Science* **350**, 1193–1198 (2015).
- 713 18. Demanelis, K. *et al.* Determinants of telomere length across human tissues. *Science* **369**, eaaz6876
714 (2020).
- 715 19. Codd, V. *et al.* Identification of seven loci affecting mean telomere length and their association with
716 disease. *Nat. Genet.* **45**, 422–7, 427e1-2 (2013).
- 717 20. Alexeeff, S. E. *et al.* Telomere length and socioeconomic status at neighborhood and individual levels
718 among 80,000 adults in the Genetic Epidemiology Research on Adult Health and Aging cohort. *Environ.*

- 719 *Epidemiol.* **3**, e049 (2019).
- 720 21. Allaire, P. *et al.* Genetic and clinical determinants of telomere length. *HGG Adv* **4**, 100201 (2023).
- 721 22. Codd, V. *et al.* Measurement and initial characterization of leukocyte telomere length in 474,074
722 participants in UK Biobank. *Nat Aging* **2**, 170–179 (2022).
- 723 23. Rewak, M. *et al.* Race-related health disparities and biological aging: does rate of telomere shortening
724 differ across blacks and whites? *Biol. Psychol.* **99**, 92–99 (2014).
- 725 24. Taub, M. A. *et al.* Genetic determinants of telomere length from 109,122 ancestrally diverse whole-
726 genome sequences in TOPMed. *Cell Genom.* **2**, 100084 (2022).
- 727 25. Burren, O. S. *et al.* Genetic architecture of telomere length in 462,666 UK Biobank whole-genome
728 sequences. *Nat. Genet.* **56**, 1832–1840 (2024).
- 729 26. Ding, Z. *et al.* Estimating telomere length from whole genome sequence data. *Nucleic Acids Res.* **42**, e75
730 (2014).
- 731 27. Pedersen, B. S. & Quinlan, A. R. Mosdepth: quick coverage calculation for genomes and exomes.
732 *Bioinformatics* **34**, 867–868 (2018).
- 733 28. Lee, M., Martin, H., Firpo, M. A. & Demerath, E. W. Inverse association between adiposity and telomere
734 length: The Fels Longitudinal Study. *Am. J. Hum. Biol.* **23**, 100–106 (2011).
- 735 29. Tellechea, M. L. & Pirola, C. J. The impact of hypertension on leukocyte telomere length: a systematic
736 review and meta-analysis of human studies. *J. Hum. Hypertens.* **31**, 99–105 (2017).
- 737 30. Huang, Y.-Q. *et al.* The relationship between mean telomere length and blood pressure: results from the
738 National Health and Nutrition Examination Surveys. *Ann. Transl. Med.* **8**, 535 (2020).
- 739 31. Chen, Y.-F., Zhou, K.-W., Yang, G.-Z. & Chen, C. Association between lipoproteins and telomere
740 length in US adults: data from the NHANES 1999-2002. *Lipids Health Dis.* **18**, 80 (2019).
- 741 32. Topiwala, A. *et al.* Alcohol consumption and telomere length: Mendelian randomization clarifies
742 alcohol's effects. *Mol. Psychiatry* **27**, 4001–4008 (2022).
- 743 33. Denny, J. C. *et al.* PheWAS: demonstrating the feasibility of a phenome-wide scan to discover gene-
744 disease associations. *Bioinformatics* **26**, 1205–1210 (2010).
- 745 34. Wei, W.-Q. *et al.* Evaluating phecodes, clinical classification software, and ICD-9-CM codes for
746 phenome-wide association studies in the electronic health record. *PLoS One* **12**, e0175508 (2017).
- 747 35. de Lange, T. *et al.* Structure and variability of human chromosome ends. *Mol. Cell. Biol.* **10**, 518–527
748 (1990).
- 749 36. Hastie, N. D. *et al.* Telomere reduction in human colorectal carcinoma and with ageing. *Nature* **346**,
750 866–868 (1990).
- 751 37. Nakao, T. *et al.* Mendelian randomization supports bidirectional causality between telomere length and
752 clonal hematopoiesis of indeterminate potential. *Sci Adv* **8**, eabl6579 (2022).
- 753 38. Kessler, M. D. *et al.* Common and rare variant associations with clonal haematopoiesis phenotypes.
754 *Nature* **612**, 301–309 (2022).
- 755 39. Bulik-Sullivan, B. *et al.* An atlas of genetic correlations across human diseases and traits. *Nat. Genet.* **47**,
756 1236–1241 (2015).
- 757 40. Denchi, E. L. & de Lange, T. Protection of telomeres through independent control of ATM and ATR by
758 TRF2 and POT1. *Nature* **448**, 1068–1071 (2007).
- 759 41. Weeks, E. M. *et al.* Leveraging polygenic enrichments of gene features to predict genes underlying
760 complex traits and diseases. *Nat. Genet.* **55**, 1267–1276 (2023).

- 761 42. Khandanpour, C. *et al.* Evidence that growth factor independence 1b regulates dormancy and peripheral
762 blood mobilization of hematopoietic stem cells. *Blood* **116**, 5149–5161 (2010).
- 763 43. Bao, E. L. *et al.* Inherited myeloproliferative neoplasm risk affects haematopoietic stem cells. *Nature*
764 **586**, 769–775 (2020).
- 765 44. Lu, R. *et al.* The FANCM-BLM-TOP3A-RMI complex suppresses alternative lengthening of telomeres
766 (ALT). *Nat. Commun.* **10**, 2252 (2019).
- 767 45. Martinsson-Ahlzén, H.-S. *et al.* Cyclin-dependent kinase-associated proteins Cks1 and Cks2 are essential
768 during early embryogenesis and for cell cycle progression in somatic cells. *Mol. Cell. Biol.* **28**, 5698–
769 5709 (2008).
- 770 46. Zhou, C., Bae-Jump, V. L., Whang, Y. E., Gehrig, P. A. & Bogges, J. F. The PTEN tumor suppressor
771 inhibits telomerase activity in endometrial cancer cells by decreasing hTERT mRNA levels. *Gynecol.*
772 *Oncol.* **101**, 305–310 (2006).
- 773 47. Seo, S.-H., Shin, J.-H., Ham, D.-W. & Shin, E.-H. PTEN/AKT signaling pathway related to hTERT
774 downregulation and telomere shortening induced in Toxoplasma GRA16-expressing colorectal cancer
775 cells. *Biomed. Pharmacother.* **153**, 113366 (2022).
- 776 48. Keener, R. *et al.* Validation of human telomere length trans-ancestry meta-analysis association signals
777 identifies *POP5* and *KBTBD6* as novel human telomere length regulation genes. *bioRxiv*
778 2023.07.12.548702 (2023) doi:10.1101/2023.07.12.548702.
- 779 49. Tseng, C.-K. *et al.* Human Telomerase RNA Processing and Quality Control. *Cell Rep.* **13**, 2232–2243
780 (2015).
- 781 50. Drosopoulos, W. C., Kosiyatrakul, S. T. & Schildkraut, C. L. BLM helicase facilitates telomere
782 replication during leading strand synthesis of telomeres. *J. Cell Biol.* **210**, 191–208 (2015).
- 783 51. Chang, Y. *et al.* Unraveling the causal genes and transcriptomic determinants of human telomere length.
784 *Nat. Commun.* **14**, 8517 (2023).
- 785 52. Zeng, S. *et al.* Telomere recombination requires the MUS81 endonuclease. *Nat. Cell Biol.* **11**, 616–623
786 (2009).
- 787 53. Li, V. S. W. *et al.* Wnt signaling through inhibition of β -catenin degradation in an intact Axin1 complex.
788 *Cell* **149**, 1245–1256 (2012).
- 789 54. Hoffmeyer, K. *et al.* Wnt/ β -catenin signaling regulates telomerase in stem cells and cancer cells. *Science*
790 **336**, 1549–1554 (2012).
- 791 55. Fernandez, R. J., 3rd & Johnson, F. B. A regulatory loop connecting WNT signaling and telomere
792 capping: possible therapeutic implications for dyskeratosis congenita: WNT and telomere capping in
793 dyskeratosis congenita. *Ann. N. Y. Acad. Sci.* **1418**, 56–68 (2018).
- 794 56. Feretzaki, M. *et al.* RAD51-dependent recruitment of TERRA lncRNA to telomeres through R-loops.
795 *Nature* **587**, 303–308 (2020).
- 796 57. Benner, C. *et al.* FINEMAP: efficient variable selection using summary data from genome-wide
797 association studies. *Bioinformatics* **32**, 1493–1501 (2016).
- 798 58. Buemi, V. *et al.* TGS1 mediates 2,2,7-trimethyl guanosine capping of the human telomerase RNA to
799 direct telomerase dependent telomere maintenance. *Nat. Commun.* **13**, 2302 (2022).
- 800 59. Sharma, R. *et al.* Gain-of-function mutations in RPA1 cause a syndrome with short telomeres and
801 somatic genetic rescue. *Blood* **139**, 1039–1051 (2022).
- 802 60. Liu, S. *et al.* RING finger and WD repeat domain 3 (RFWD3) associates with replication protein A
803 (RPA) and facilitates RPA-mediated DNA damage response. *J. Biol. Chem.* **286**, 22314–22322 (2011).
- 804 61. Ogawa, S. *et al.* Zscan5b Deficiency Impairs DNA Damage Response and Causes Chromosomal


- 805 Aberrations during Mitosis. *Stem Cell Reports* **12**, 1366–1379 (2019).
- 806 62. Revy, P., Kannengiesser, C. & Bertuch, A. A. Genetics of human telomere biology disorders. *Nat. Rev.*
807 *Genet.* **24**, 86–108 (2023).
- 808 63. Staněk, D. Coilin and Cajal bodies. *Nucleus* **14**, 2256036 (2023).
- 809 64. Chen, L.-Y., Redon, S. & Lingner, J. The human CST complex is a terminator of telomerase activity.
810 *Nature* **488**, 540–544 (2012).
- 811 65. Lim, C. J. & Cech, T. R. Shaping human telomeres: from shelterin and CST complexes to telomeric
812 chromatin organization. *Nat. Rev. Mol. Cell Biol.* **22**, 283–298 (2021).
- 813 66. Mannherz, W. & Agarwal, S. Thymidine nucleotide metabolism controls human telomere length. *Nat.*
814 *Genet.* **55**, 568–580 (2023).
- 815 67. Wang, H., Schumacher, A. E., Levitz, C. E., Mokdad, A. H. & Murray, C. J. Left behind: widening
816 disparities for males and females in US county life expectancy, 1985-2010. *Popul. Health Metr.* **11**, 8
817 (2013).
- 818 68. Myers, C. A., Slack, T., Martin, C. K., Broyles, S. T. & Heymsfield, S. B. Regional disparities in obesity
819 prevalence in the United States: A spatial regime analysis: Regional Disparities in Adult Obesity.
820 *Obesity (Silver Spring)* **23**, 481–487 (2015).
- 821 69. Barker, L. E., Kirtland, K. A., Gregg, E. W., Geiss, L. S. & Thompson, T. J. Geographic distribution of
822 diagnosed diabetes in the U.S.: a diabetes belt. *Am. J. Prev. Med.* **40**, 434–439 (2011).
- 823 70. Parcha, V. *et al.* Geographic variation in cardiovascular health among American adults. *Mayo Clin. Proc.*
824 **96**, 1770–1781 (2021).
- 825 71. Weeks, W. B. *et al.* Rural-urban disparities in health outcomes, clinical care, health behaviors, and social
826 determinants of health and an action-oriented, dynamic tool for visualizing them. *PLOS Glob. Public*
827 *Health* **3**, e0002420 (2023).
- 828 72. Karimian, K. *et al.* Human telomere length is chromosome end-specific and conserved across
829 individuals. *Science* **384**, 533–539 (2024).
- 830 73. All of Us Research Program Investigators *et al.* The “All of Us” Research Program. *N. Engl. J. Med.*
831 **381**, 668–676 (2019).
- 832 74. All of Us Research Program Genomics Investigators. Genomic data in the All of Us Research Program.
833 *Nature* **627**, 340–346 (2024).
- 834 75. Bycroft, C. *et al.* The UK Biobank resource with deep phenotyping and genomic data. *Nature* **562**, 203–
835 209 (2018).
- 836 76. Van Hout, C. V. *et al.* Exome sequencing and characterization of 49,960 individuals in the UK Biobank.
837 *Nature* **586**, 749–756 (2020).
- 838 77. Farmery, J. H. R., Smith, M. L., NIHR BioResource - Rare Diseases & Lynch, A. G. Telomerecat: A
839 ploidy-agnostic method for estimating telomere length from whole genome sequencing data. *Sci. Rep.* **8**,
840 1300 (2018).
- 841 78. Bonfield, J. K. *et al.* HTSlib: C library for reading/writing high-throughput sequencing data. *Gigascience*
842 **10**, (2021).
- 843 79. Master, H. *et al.* Association of step counts over time with the risk of chronic disease in the All of Us
844 Research Program. *Nat. Med.* **28**, 2301–2308 (2022).
- 845 80. Brokamp, C. *et al.* Material community deprivation and hospital utilization during the first year of life:
846 an urban population-based cohort study. *Ann. Epidemiol.* **30**, 37–43 (2019).
- 847 81. Vlasschaert, C. *et al.* A practical approach to curate clonal hematopoiesis of indeterminate potential in

- 848 human genetic data sets. *Blood* **141**, 2214–2223 (2023).
- 849 82. Cibulskis, K. *et al.* Sensitive detection of somatic point mutations in impure and heterogeneous cancer
850 samples. *Nat. Biotechnol.* **31**, 213–219 (2013).
- 851 83. Jaiswal, S. *et al.* Age-Related Clonal Hematopoiesis Associated with Adverse Outcomes. *N. Engl. J.*
852 *Med.* **371**, 2488–2498 (2014).
- 853 84. Kulldorff, M. A spatial scan statistic. *Communications in Statistics - Theory and Methods* **26**, 1481–1496
854 (1997).
- 855 85. Pebesma, E. & Bivand, R. Spatial Data Science: With Applications in R. <https://r-spatial.org/book/>
856 (2023).
- 857 86. Wickham, H. ggplot2: Elegant Graphics for Data Analysis. Preprint at <https://ggplot2.tidyverse.org>
858 (2016).
- 859 87. M’Charek, A. *The Human Genome Diversity Project: An Ethnography of Scientific Practice.*
860 (Cambridge University Press, 2005).
- 861 88. 1000 Genomes Project Consortium *et al.* A global reference for human genetic variation. *Nature* **526**,
862 68–74 (2015).
- 863 89. Karczewski, K. J. *et al.* The mutational constraint spectrum quantified from variation in 141,456 humans.
864 *Nature* **581**, 434–443 (2020).
- 865 90. Frankish, A. *et al.* GENCODE 2021. *Nucleic Acids Res.* **49**, D916–D923 (2021).
- 866 91. Price, A. L. *et al.* Long-range LD can confound genome scans in admixed populations. *The American*
867 *Journal of Human Genetics* vol. 83 132–5; author reply 135-9 (2008).
- 868 92. Van der Auwera, G. A. & O’Connor, B. D. *Genomics in the Cloud: Using Docker, GATK, and WDL in*
869 *Terra.* (“O’Reilly Media, Inc.,” 2020).
- 870 93. Sofer, T. *et al.* A fully adjusted two-stage procedure for rank-normalization in genetic association
871 studies. *Genet. Epidemiol.* **43**, 263–275 (2019).
- 872 94. Mbatchou, J. *et al.* Computationally efficient whole-genome regression for quantitative and binary traits.
873 *Nat. Genet.* **53**, 1097–1103 (2021).
- 874 95. Li, C. *et al.* Genome-wide Association Analysis in Humans Links Nucleotide Metabolism to Leukocyte
875 Telomere Length. *Am. J. Hum. Genet.* **106**, 389–404 (2020).
- 876 96. Dorajoo, R. *et al.* Loci for human leukocyte telomere length in the Singaporean Chinese population and
877 trans-ethnic genetic studies. *Nat. Commun.* **10**, 2491 (2019).
- 878 97. Delgado, D. A. *et al.* Genome-wide association study of telomere length among South Asians identifies a
879 second RTEL1 association signal. *J. Med. Genet.* **55**, 64–71 (2018).
- 880 98. Mangino, M. *et al.* DCAF4, a novel gene associated with leucocyte telomere length. *J. Med. Genet.* **52**,
881 157–162 (2015).
- 882 99. Saxena, R. *et al.* Genome-wide association study identifies variants in casein kinase II (CSNK2A2) to be
883 associated with leukocyte telomere length in a Punjabi Sikh diabetic cohort. *Circ. Cardiovasc. Genet.* **7**,
884 287–295 (2014).
- 885 100. Pooley, K. A. *et al.* A genome-wide association scan (GWAS) for mean telomere length within the
886 COGS project: identified loci show little association with hormone-related cancer risk. *Hum. Mol. Genet.*
887 **22**, 5056–5064 (2013).
- 888 101. Lee, J. H. *et al.* Genome wide association and linkage analyses identified three loci-4q25, 17q23.2, and
889 10q11.21-associated with variation in leukocyte telomere length: the Long Life Family Study. *Front.*
890 *Genet.* **4**, 310 (2013).

- 891 102. Mangino, M. *et al.* Genome-wide meta-analysis points to CTC1 and ZNF676 as genes regulating
892 telomere homeostasis in humans. *Hum. Mol. Genet.* **21**, 5385–5394 (2012).
- 893 103. Prescott, J. *et al.* Genome-wide association study of relative telomere length. *PLoS One* **6**, e19635
894 (2011).
- 895 104. Levy, D. *et al.* Genome-wide association identifies *OBFC1* as a locus involved in human leukocyte
896 telomere biology. *Proc. Natl. Acad. Sci. U. S. A.* **107**, 9293–9298 (2010).
- 897 105. Mägi, R. & Morris, A. P. GWAMA: software for genome-wide association meta-analysis. *BMC*
898 *Bioinformatics* **11**, 288 (2010).
- 899 106. Mägi, R. *et al.* Trans-ethnic meta-regression of genome-wide association studies accounting for ancestry
900 increases power for discovery and improves fine-mapping resolution. *Hum. Mol. Genet.* **26**, 3639–3650
901 (2017).
- 902 107. Zhou, W. *et al.* Global Biobank Meta-analysis Initiative: Powering genetic discovery across human
903 disease. *Cell Genom* **2**, 100192 (2022).
- 904 108. Jurgens, S. J. *et al.* Rare coding variant analysis for human diseases across biobanks and ancestries. *Nat.*
905 *Genet.* **56**, 1811–1820 (2024).
- 906 109. International HapMap 3 Consortium *et al.* Integrating common and rare genetic variation in diverse
907 human populations. *Nature* **467**, 52–58 (2010).
- 908 110. Privé, F., Arbel, J. & Vilhjálmsson, B. J. LDpred2: better, faster, stronger. *Bioinformatics* **36**, 5424–5431
909 (2021).
- 910 111. Yang, J. *et al.* Common SNPs explain a large proportion of the heritability for human height. *Nat. Genet.*
911 **42**, 565–569 (2010).


912 Figures and Legends

913 Fig. 1: Overview of this study.



914
915 Leukocyte telomere length (LTL) was estimated from 242,494 blood-derived whole genome
916 sequence data from diverse participants of the National Institute of Health *All of Us* Research
917 Program (AoU) using TelSeq²⁶ and NGS-PCA²⁴. The associations with demographics, lifestyle,
918 biomarkers, phecodes, and their heterogeneity across genetic ancestries and sexes were
919 investigated. We also examined the geographical heterogeneity of LTL across the United States.
920 We performed genome-wide association studies for common and rare variants in AoU, followed
921 by meta-analyses with UK Biobank, to prioritize novel loci and genes. We further inspected
922 heterogeneities in genetic studies across genetic ancestries and sexes.


923 **Fig. 2: Associations between leukocyte telomere length and demographics/health-related**
 924 **traits in the *All of Us* Research Program.**



925
 926 **a**, Linear regression analysis of leukocyte telomere length (LTL) in the *All of Us* Research
 927 Program, examining the effects of age, genetically determined sex, and genetic ancestry on LTL,
 928 with further adjustment for sequencing site. Effect estimates for each variable are presented with
 929 95% confidence intervals. **b**, Analysis of the heterogeneity in the effect of age on LTL,
 930 stratified by genetic ancestry and sex. Effect estimates are presented with 95% confidence intervals. The
 931 linear regression model was adjusted for sex, the first 10 genetic principal components (PCs),

932 and sequencing site. Heterogeneity P -values for genetic ancestry (P_{anc_het}) and sex (P_{sex_het}) were
933 derived by Cochran's Q test. **c**, The effects of LTL on health-related traits were tested using
934 linear regression model (continuous trait) and logistic regression model (binary trait) adjusted for
935 age, sex, the first 10 genetic PCs, and sequencing site. Effect estimates for each variable are
936 presented with 95% confidence intervals. **d**, The heterogeneities of associations between LTL
937 and traits across genetic ancestries and sexes were tested using Cochran's Q test. Bars with high
938 transparency indicate non-significance, while opaque bars indicate significance at $\alpha < 0.05$ with
939 Bonferroni correction ($P < 0.0021$). AFR: African-like population, AMR: Admixed American-
940 like population, BP: blood pressure, CI: confidence interval, EAS: East Asian-like population,
941 EUR: European-like population, LDL: low-density lipoprotein, HDL: high-density lipoprotein,
942 MID: Middle Eastern-like population, N. deprivation index: neighborhood deprivation index,
943 SAS: South Asian-like population, SD: standard deviation.


944 **Fig. 3: Phenome-wide association study and geographic analysis of leukocyte telomere**
 945 **length in the *All of Us* Research Program.**



946


947 **a**, Associations between phecodes and leukocyte telomere length (LTL) were tested by logistic
948 regression model adjusting for age, sex, sequencing site, and first 10 genetic principal
949 components (PCs). **b**, Heterogeneity of associations between phecode and LTL across genetic
950 ancestries (upward) and sexes (downward) assessed by Cochran’s Q test. **c**, Geographical
951 heterogeneity of LTL among participants across the United States was assessed by linear
952 regression model adjusted with age, sex, first 10 genetic PCs, and sequencing site. Significant
953 clusters were detected by SatScan⁸⁴.

954 **Fig. 4: Genetic ancestry- and sex-specific loci in meta-analyses of common-variant genome-**
 955 **wide association studies.**




956
 957 Genome-wide association studies in the *All of Us* Research Program and UK Biobank using
 958 common variants (minor allele frequency > 0.1%) were meta-analyzed in each genetic ancestry
 959 with fixed effect model. Genome-wide significant loci ($P < 5 \times 10^{-8}$) specific in African-like
 960 population (AFR) (**a-d**) and specific in females (**e** and **f**) were displayed by locuszoom plot
 961 (**a,c,e**) and effect estimates and 95% confidence intervals in each population (**b,d,f**). AF: allele
 962 frequency, AFR: African-like population, EAF: effect allele frequency, EAS: East Asian-like
 963 population, EUR: European-like population, SAS: South Asian-like population.

964 **Fig. 5: Meta-analysis of rare variant aggregation test for leukocyte telomere length in the**
 965 ***All of Us* Research Program and UK Biobank.**



966 We performed multi-ancestry meta-analysis of genome-wide rare variant aggregation tests for
 967 leukocyte telomere length (LTL) in the *All of Us* Research Program and UK Biobank. **a**, Upward
 968 triangle means association with longer LTL, downward with shorter LTL. Red text indicates
 969 novel genes. Box colors indicate functional categories. **b**, genome-wide significant genes ($P <$
 970 2.5×10^{-6}) were classified by function and plotted with the effect size on the y-axis. Red text
 971 indicates novel genes.
 972


973 **Extended Data Fig. 1: Telomere length estimation using whole genome sequence data.**



974
 975 **a**, Telomerecat and TelSeq were compared for the agreement with quantitative polymerase chain
 976 reaction measurements within the same random 1,000 samples in the UK Biobank (UKB) for
 977 leukocyte telomere length (LTL) estimation using whole genome sequence (WGS) data. R^2 was
 978 calculated by Pearson correlation. **b**, Estimated LTL was compared between modified TelSeq vs
 979 original TelSeq (v0.0.2) for random 1,000 samples in UKB. **c** and **d**, Modified TelSeq software
 980 was compared with original software for time (**c**) and cost (**d**) for random 100 WGS on UKB-


981 RAP. **e** and **f**, The effect estimates (**e**) and *P*-values (**f**) of the independent sentinel variants in
982 previous UKB for LTL were compared with the *All of Us* Research Program (AoU) between
983 original LTL call and LTL adjusted by WGS-depth derived principal components (NGS-PCs) in
984 European-like population.

985 **Extended Data Fig. 2: Associations between leukocyte telomere length (LTL)/LTL-**
 986 **polygenic score (PGS)/LTL-residual and health-related traits in European-like population**
 987 **in the *All of Us* Research Program.**



988
 989 The effects of leukocyte telomere length (LTL), polygenic score for LTL (LTL-PGS), and LTL
 990 residualized by LTL-PGS (LTL-residual) on health-related traits were tested in European-like
 991 population using linear regression model (continuous trait) and logistic regression model (binary
 992 trait) adjusted for age, sex, the first 10 genetic principal components, and sequencing site. BP:
 993 blood pressure, LDL: low-density lipoprotein, HDL: high-density lipoprotein, N. Deprivation
 994 Index: neighborhood deprivation index.


995 **Extended Data Fig. 3: Phenome-wide association study of leukocyte telomere length-**
 996 **polygenic score (LTL-PGS) and LTL residualized by LTL-PGS (LTL-residual).**



997
 998 Associations between polygenic score for LTL (LTL-PGS) (**a**) and LTL residualized by LTL-
 999 PGS (LTL-residual) (**b**) and prevalent phecodes were assessed by logistic regression model
 1000 adjusting with age, sex, first 10 genetic principal components, and sequencing site in the *All of*
 1001 *Us* Research Program. Upward triangles indicate positive associations, and downward triangles

1002 indicate negative associations. Phecodes with less than 10 cases were excluded from the
1003 analyses.


1004 **Extended Data Fig. 4: Association with clonal hematopoiesis of indeterminate potential**
1005 **(CHIP).**




1006 Associations between leukocyte telomere length (LTL) and clonal hematopoiesis of
1007 indeterminate potential (CHIP) were assessed by logistic regression model adjusting with age,
1008 sex, first 10 genetic principal components, and sequencing site. DDR: DNA damage repair.
1009

1010 **Extended Data Fig. 5: State-level heterogeneity of leukocyte telomere length (LTL) in the**
1011 **United States and sensitivity analyses of geographic heterogeneity.**


a




b




c




d




e



f




g



1012 **a**, State-level heterogeneity of the leukocyte telomere length (LTL) across the United States was
1013 tested with linear regression model adjusting for age, sex, first 10 genetic principal components
1014


1015 (PCs), and sequencing site. **b-d**, Geographical heterogeneity at 3 ZIP code prefix level was
1016 tested with linear regression model adjusted for additional covariates (**b**: body mass index
1017 [BMI], **c**: ever smoking, **d**: neighborhood deprivation index) in addition to age, sex, first 10
1018 genetic principal components (PCs), and sequencing site. **e-g**, Geographical heterogeneity at 3
1019 ZIP code prefix level was tested in European-like population (EUR) for LTL (**e**), LTL-PGS (**f**),
1020 and LTL-residual (**g**) with linear regression model adjusted for age, sex, first 10 genetic PCs, and
1021 sequencing site.

1022 **Extended Data Fig. 6: Genome-wide association study in the *All of Us* Research Program.**




1023
 1024 Genome-wide association studies for common variants (minor allele frequency > 0.1%) were
 1025 performed by Regenie⁹⁴ adjusting for age, sex, the first 10 genetic principal components, and
 1026 sequencing site in the *All of Us* Research Program separately for African-like population (AFR)
 1027 (a), Admixed American-like population (AMR) (b), East Asian-like population (EAS) (c),
 1028 European-like population (EUR) (d), and South Asian-like population (SAS) (e). Genomic
 1029 control with linkage disequilibrium score regression intercept was applied. f, The locuszoom
 1030 for a novel locus at 3q23 in EUR.

1031 **Extended Data Fig. 7: Genome-wide association study meta-analyses for leukocyte**
 1032 **telomere length (LTL) with the *All of Us* Research Program and UK Biobank.**




1033
 1034 Fixed effect meta-analyses for common variant genome-wide association studies (GWASs) were
 1035 performed for the *All of Us* Research Program and UK Biobank, separately for African-like
 1036 population (AFR) (a), East Asian-like population (EAS) (b), European-like population (EUR)
 1037 (c), and South Asian-like population (SAS) (d). We only included variants found in both cohorts.
 1038 Blue represents previously known significant loci ($P < 5 \times 10^{-8}$), and red represents novel
 1039 significant loci. e, Genetic ancestry- and sex-specific genomic predispositions were investigated
 1040 in the GWAS meta-analyses. Manhattan plots for each genetic ancestry are plotted in different
 1041 colors depending on the genetic ancestry as the upward part of the Miami plot. The heterogeneity
 1042 P between sexes calculated by GWAMA is plotted downward in the Miami plot.

1043 **Extended Data Fig. 8: Locuszoom for a part of novel loci in meta-analysis.**



1044 The locuszoom plots for example novel loci in genome-wide association study meta-analyses
 1045 with FINEMAP⁵⁷ and PoPS⁴¹ annotations. Red texts indicate the nearest and PoPS prioritized
 1046 genes. EUR: European-like population.
 1047


1048 **Extended Data Fig. 9: Multi-ancestry meta-analysis for common variant genome-wide**
 1049 **association studies.**



1050
 1051 **a**, Principal components calculated by MR-MEGA¹⁰⁶ to correct the population structures for
 1052 multi-ancestry genome-wide association study (GWAS) meta-analysis, which effectively

1053 distinguished genetic ancestries. **b** and **c**, We performed multi-ancestry GWAS meta-analysis for
1054 common variants in the *All of Us* Research Program (AoU) and UK Biobank (UKB). We
1055 implemented genomic correction by linkage disequilibrium score regression intercept before
1056 meta-analysis and found no evidence of inflation ($\lambda_{GC} = 1.086$). Manhattan plot (**b**) shows
1057 previously known significant ($P < 5 \times 10^{-8}$) loci in blue and novel significant loci in red. QQ plot
1058 (**c**) of multi-ancestry GWAS in this study (red) and previous meta-analysis of UKB, Trans-
1059 Omics for Precision Medicine (TOPMed), and Singapore Chinese Health Study (SCHS)⁵¹(green)
1060 and UKB⁴ (blue). **d** and **e**, The locuszoom plots for the example novel loci in multi-ancestry
1061 GWAS meta-analysis for common variants. Red texts indicate the nearest and PoPS prioritized
1062 genes.

1063 **Extended Data Fig. 10: Improved performance of polygenic score in African-like**
1064 **population (AFR).**



1065 We calculated polygenic scores (PGS) for leukocyte telomere length using LDpred2, with
1066 weights derived from training genetic ancestries in the respective cohorts. To do this, we
1067 performed genome-wide association studies (GWASs) in the All of Us Research Program
1068 (AoU), excluding a random sample of 10,000 individuals per genetic ancestry. The resulting
1069 summary statistics were used for meta-analysis with UK Biobank (UKB). We optimized
1070 hyperparameters based on the best-performing partial R^2 in a random 2,000-sample subset held
1071 out from the GWAS. We then evaluated the final performance of the PGS (partial R^2) in the
1072 remaining 8,000 held-out samples in AoU. AFR: African-like population, EUR: European-like
1073 population.
1074